Guidelines for the treatment of autoimmune neuromuscular transmission disorders

European Journal of Neurology

Volumn 13, Issue 7, 2006, Pages 691-699

  Skeie, G O ^a,j   Apostolski, S ^b   Evoli, A ^c   Gilhus, N E ^a   Hart, I K ^d   Harms, L ^e   Hilton Jones, D ^f   Melms, A ^g   Verschuuren, J ^h   Horge, H W ⁱ  

^a UNIVERSITY OF BERGEN   (Norway)

^b UNIVERSITY OF BELGRADE   (Serbia)

^c Catholic University   (Serbia)

^d WALTON CENTRE FOR NEUROLOGY AND NEUROSURGERY   (United Kingdom)

^e CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^f RADCLIFFE INFIRMARY   (United Kingdom)

^g UNIVERSITY OF TÜBINGEN   (Germany)

^h LUMC   (Serbia)

ⁱ Norwegian Muscularly Disorders Association   (Serbia)

^j HAUKELAND UNIVERSITY HOSPITAL   (Norway)

more..

Author keywords

Lambert Eaton myasthenic syndrome; Myasthenia gravis; Neuromuscular transmission disorders; Neuromyotonia

Indexed keywords

3,4 DIAMINOPYRIDINE; ANTICONVULSIVE AGENT; AZATHIOPRINE; CARBAMAZEPINE; CHOLINESTERASE INHIBITOR; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN; IMMUNOGLOBULIN; IMMUNOSUPPRESSIVE AGENT; LAMOTRIGINE; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PHENYTOIN; PREDNISOLONE; PYRIDOSTIGMINE; RITUXIMAB; STEROID; TACROLIMUS; VALPROIC ACID;

ABNORMALLY HIGH SUBSTRATE CONCENTRATION IN BLOOD; ANEMIA; ANXIETY; ARTHROGRYPOSIS; ARTICLE; AUTOIMMUNE DISEASE; BONE MARROW SUPPRESSION; BRADYCARDIA; CATARACT; CLINICAL TRIAL; COCHRANE LIBRARY; DEPRESSION; DIABETES MELLITUS; DIARRHEA; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG SAFETY; EATON LAMBERT SYNDROME; EMBASE; FASCICULATION; FLU LIKE SYNDROME; FLUID RETENTION; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL SECRETION; GASTROINTESTINAL SYMPTOM; GLAUCOMA; HEPATITIS; HUMAN; HYPERHIDROSIS; HYPERTENSION; IMMUNOSUPPRESSIVE TREATMENT; INFERTILITY; INSOMNIA; INTESTINAL DYSMOTILITY; JOINT NECROSIS; LEUKOPENIA; MEDICAL PRACTICE; MEDLINE; MUSCLE CRAMP; MUSCLE WEAKNESS; MYASTHENIA GRAVIS; MYOKYMIA; MYOPATHY; NEPHROTOXICITY; NEUROMUSCULAR TRANSMISSION; OPHTHALMOPLEGIA; OPPORTUNISTIC INFECTION; PANCREATITIS; PANCYTOPENIA; PERFORATION; PLASMAPHERESIS; PRACTICE GUIDELINE; PRIORITY JOURNAL; PSYCHOSIS; SIDE EFFECT; SWEATING; THROMBOCYTOPENIA; THYMECTOMY; WEIGHT CONTROL; WEIGHT GAIN;

EID: 33746534220     PISSN: 13515101     EISSN: 14681331     Source Type: Journal    
DOI: 10.1111/j.1468-1331.2006.01476.x     Document Type: Article

References (78)

1. Brainin M, Barnes M, Baron JC, et al. Guidance for the preparation of neurological management guidelines by EFNS scientific task forces - revised recommendations 2004. European Journal of Neurology 2004; 11: 577-581.
2. Vincent A. Unravelling the pathogenesis of myasthenia gravis. Nature Reviews. Immunology 2002; 2: 797-804.
3. Hoch W, McConville J, Helms S, Newsom-Davis J, Melms A, Vincent A. Auto-antibodies to the receptor tyrosine kinase MuSK in patients with myasthenia gravis without acetylcholine receptor antibodies. Nature Medicine 2001; 7: 365-368.
4. Aarli JA, Stefansson K, Marton LS, Wollmann RL. Patients with myasthenia gravis and thymoma have in their sera IgG autoantibodies against titin. Clinical and Experimental Immunology 1990; 82: 284-288.
5. Mygland A, Tysnes OB, Matre R, Volpe P, Aarli JA, Gilhus NE. Ryanodine receptor autoantibodies in myasthenia gravis patients with a thymoma. Annals of Neurology 1992; 32: 589-591.
6. Skeie GO, Mygland A, Aarli JA, Gilhus NE. Titin antibodies in patients with late onset myasthenia gravis: clinical correlations. Autoimmunity 1995; 20: 99-104.
7. Somnier FE, Skeie GO, Aarli JA, Trojaborg W. EMG evidence of myopathy and the occurrence of titin autoantibodies in patients with myasthenia gravis. European Journal of Neurology 1999; 6: 555-563.
8. Gerber NL, Steinberg AD. Clinical use of immunosuppressive drugs: part II. Drugs 1976; 11: 90-112.
9. Szathmary I, Magyar P, Szobor A. Air-flow limitation in myasthenia gravis. The effect of acetylcholinesterase inhibitor therapy on air-flow limitation. The American Review of Respiratory Disease 1984; 130: 145.
10. Shale DJ, Lane DJ, Davis CJ. Air-flow limitation in myasthenia gravis. The effect of acetylcholinesterase inhibitor therapy on air-flow limitation. The American Review of Respiratory Disease 1983; 128: 618-621.
11. Sghirlanzoni A, Pareyson D, Benvenuti C, et al. Efficacy of intranasal administration of neostigmine in myasthenic patients. Journal of Neurology 1992; 239: 165-169.
12. Sieb JP, Engel AG. Ephedrine: effects on neuromuscular transmission. Brain Research 1993; 623: 167-171.
13. Anlar B, Varli K, Ozdirim E, Ertan M. 3,4-diaminopyridine in childhood myasthenia: double-blind, placebo-controlled trial. Journal of Child Neurology 1996; 11: 458-461.
14. Romi F, Skeie GO, Aarli JA, Gilhus NE. The severity of myasthenia gravis correlates with the serum concentration of titin and ryanodine receptor antibodies. Archives of Neurology 2000; 57: 1596-1600.
15. Gajdos P, Chevret S, Toyka K. Plasma exchange for myasthenia gravis. Cochrane Database of Systematic Reviews 2002; 4: CD002275.
16. Perlo VP, Shahani BT, Huggins CE, Hunt J, Kosinski K, Potts F. Effect of plasmapheresis in myasthenia gravis. Annals of the New York Academy of Sciences 1981; 377: 709-724.
17. Dau PC. Plasmapheresis therapy in myasthenia gravis. Muscle and Nerve 1980; 3: 468-482.
18. Olarte MR, Schoenfeldt RS, Penn AS, Lovelace RE, Rowland LP. Effect of plasmapheresis in myasthenia gravis 1978-1980. Annals of the New York Academy of Sciences 1981; 377: 725-728.
19. Gajdos P, Simon N, de Rohan-Chabot P, Raphael JC, Goulon M. Long-term effects of plasma exchange in myasthenia. Results of a randomized study. Presse Medicale 1983; 12: 939-942.
20. Fateh-Moghadam A, Wick M, Besinger U, Geursen RG. High-dose intravenous gammaglobulin for myasthenia gravis. Lancet 1984; 1: 848-849.
21. Dalakas MC. Intravenous immunoglobulin in the treatment of autoimmune neuromuscular diseases: present status and practical therapeutic guidelines. Muscle and Nerve 1999; 22: 1479-1497.
22. Gajdos P, Chevret S, Toyka K. Intravenous immunoglobulin for myasthenia gravis. Cochrane Database of Systematic Reviews 2003; 2: CD002277.
23. Gajdos P, Chevret S, Clair B, Tranchant C, Chastang C. Clinical trial of plasma exchange and high-dose intravenous immunoglobulin in myasthenia gravis. Myasthenia Gravis Clinical Study Group. Annals of Neurology 1997; 41: 789-796.
24. Buckingham JM, Howard FM Jr, Bernatz PE, et al. The value of thymectomy in myasthenia gravis: a computer-assisted matched study. Annals of Surgery 1976; 184: 453-458.
25. Gronseth GS, Barohn RJ. Thymectomy for myasthenia gravis. Current Treatment Options in Neurology 2002; 4: 203-209.
26. Gronseth GS, Barohn RJ. Practice parameter: thymectomy for autoimmune myasthenia gravis (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2000; 55: 7-15.
27. Guillermo GR, Tellez-Zenteno JF, Weder-Cisneros N, et al. Response of thymectomy: clinical and pathological characteristics among seronegative and seropositive myasthenia gravis patients. Acta Neurologica Scandinavica 2004; 109: 217-221.
28. Evoli A, Tonali PA, Padua L, et al. Clinical correlates with anti-MuSK antibodies in generalized seronegative myasthenia gravis. Brain 2003; 126(Pt 10):2304-2311.
29. Reinhardt C, Melms A. Normalization of elevated CD4-/ CD8- (double-negative) T cells after thymectomy parallels clinical remission in myasthenia gravis associated with thymic hyperplasia but not thymoma. Annals of Neurology 2000; 48: 603-608.
30. Chen G, Marx A, Wen-Hu C, et al. New WHO histologic classification predicts prognosis of thymic epithelial tumors: a clinicopathologic study of 200 thymoma cases from China. Cancer 2002; 95: 420-429.
31. Pascuzzi RM, Coslett HB, Johns TR. Long-term corticosteroid treatment of myasthenia gravis: report of 116 patients. Annals of Neurology 1984; 15: 291-298.
32. Saag KG. Prevention of glucocorticoid-induced osteoporosis. Southern Medical Journal 2004; 97: 555-558.
33. Palace J, Newsom-Davis J, Lecky B. A randomized double-blind trial of prednisolone alone or with azathioprine in myasthenia gravis. Myasthenia Gravis Study Group. Neurology 1998; 50: 1778-1783.
34. Witte AS, Cornblath DR, Parry GJ, Lisak RP, Schatz NJ. Azathioprine in the treatment of myasthenia gravis. Annals of Neurology 1984; 15: 602-605.
35. Bromberg MB, Wald JJ, Forshew DA, Feldman EL, Albers JW. Randomized trial of azathioprine or prednisone for initial immunosuppressive treatment of myasthenia gravis. Journal of the Neurological Sciences 1997; 150: 59-62.
36. De Feo LG, Schottlender J, Martelli NA, Molfino NA. Use of intravenous pulsed cyclophosphamide in severe, generalized myasthenia gravis. Muscle and Nerve 2002; 26: 31-36.
37. Matsuda S, Koyasu S. Mechanisms of action of cyclosporine. Immunopharmacology 2000; 47: 119-125.
38. Tindall RS, Rollins JA, Phillips JT, Greenlee RG, Wells L, Belendiuk G. Preliminary results of a double-blind, randomized, placebo-controlled trial of cyclosporine in myasthenia gravis. New England Journal of Medicine 1987; 316: 719-724.
39. Tindall RS. Immunointervention with cyclosporin A in autoimmune neurological disorders. Journal of Autoimmunity 1992; 5(Suppl. A):301-313.
40. Tindall RS, Phillips JT, Rollins JA, Wells L, Hall K. A clinical therapeutic trial of cyclosporine in myasthenia gravis. Annals of the New York Academy of Sciences 1993; 681: 539-551.
41. Goulon M, Elkharrat D, Gajdos P. Treatment of severe myasthenia gravis with cyclosporin. A 12-month open trial. Presse Medicale 1989; 18: 341-346.
42. Goulon M, Elkharrat D, Lokiec F, Gajdos P. Results of a one-year open trial of cyclosporine in ten patients with severe myasthenia gravis. Transplantation Proceedings 1988; 20(Suppl. 4):211-217.
43. Bonifati DM, Angelini C. Long-term cyclosporine treatment in a group of severe myasthenia gravis patients. Journal of Neurology 1997; 244: 542-547.
44. Ciafaloni E, Nikhar NK, Massey JM, Sanders DB. Retrospective analysis of the use of cyclosporine in myasthenia gravis. Neurology 2000; 55: 448-450.
45. Ciafaloni E, Massey JM, Tucker-Lipscomb B, Sanders DB. Mycophenolate mofetil for myasthenia gravis: an open-label pilot study. Neurology 2001; 56: 97-99.
46. Chaudhry V, Cornblath DR, Griffin JW, O'Brien R, Drachman DB. Mycophenolate mofetil: a safe and promising immunosuppressant in neuromuscular diseases. Neurology 2001; 56: 94-96.
47. Schneider C, Gold R, Reiners K, Toyka KV. Mycophenolate mofetil in the therapy of severe myasthenia gravis. European Neurology 2001; 46: 79-82.
48. Hauser RA, Malek AR, Rosen R. Successful treatment of a patient with severe refractory myasthenia gravis using mycophenolate mofetil. Neurology 1998; 51: 912-913.
49. Meriggioli MN, Rowin J. Single fiber EMG as an outcome measure in myasthenia gravis: results from a double-blind, placebo-controlled trial. Journal of Clinical Neurophysiology 2003; 20: 382-385.
50. Meriggioli MN, Rowin J. Treatment of myasthenia gravis with mycophenolate mofetil: a case report. Muscle and Nerve 2000; 23: 1287-1289.
51. Meriggioli MN, Ciafaloni E, Al-Hayk KA, et al. Mycophenolate mofetil for myasthenia gravis: an analysis of efficacy, safety, and tolerability. Neurology 2003; 61: 1438-1440.
52. Timerman AP, Ogunbumni E, Freund E, Wiederrecht G, Marks AR, Fleischer S. The calcium release channel of sarcoplasmic reticulum is modulated by FK-506-binding protein. Dissociation and reconstitution of FKBP-12 to the calcium release channel of skeletal muscle sarcoplasmic reticulum. Journal of Biological Chemistry 1993; 268: 22992-22999.
53. Takamori M, Motomura M, Kawaguchi N, et al. Antiryanodine receptor antibodies and FK506 in myasthenia gravis. Neurology 2004; 62: 1894-1896.
54. Konishi T, Yoshiyama Y, Takamori M, Yagi K, Mukai E, Saida T. Clinical study of FK506 in patients with myasthenia gravis. Muscle and Nerve 2003; 28: 570-574.
55. Yoshikawa H, Mabuchi K, Yasukawa Y, Takamori M, Yamada M. Low-dose tacrolimus for intractable myasthenia gravis. Journal of Clinical Neuroscience 2002; 9: 627-628.
56. Evoli A, Di Schino C, Marsili F, Punzi C. Successful treatment of myasthenia gravis with tacrolimus. Muscle and Nerve 2002; 25: 111-114.
57. Wylam ME, Anderson PM, Kuntz NL, Rodriguez V. Successful treatment of refractory myasthenia gravis using rituximab: a pediatric case report. Journal of Pediatrics 2003; 143: 674-677.
58. AhIberg R, Yi Q, Pirskanen R, et al. Treatment of myasthenia gravis with anti-CD4 antibody: improvement correlates to decreased T-cell autoreactivity. Neurology 1994; 44: 1732-1737.
59. Weiner P, Gross D, Meiner Z, et al. Respiratory muscle training in patients with moderate to severe myasthenia gravis. Canadian Journal of Neurological Sciences 1998; 25: 236-241.
60. Lohi EL, Lindberg C, Andersen O. Physical training effects in myasthenia gravis. Archives of Physical Medicine and Rehabilitation 1993; 74: 1178-1180.
61. Hoff JM, Daltveit AK, Gilhus NE. Myasthenia gravis: consequences for pregnancy, delivery, and the newborn. Neurology 2003; 61: 1362-1366.
62. Vincent A, Newland C, Brueton L, et al. Arthrogryposis multiplex congenita with maternal autoantibodies specific for a fetal antigen. Lancet 1995; 346: 24-25.
63. Ferrero S, Pretta S, Nicoletti A, Petrera P, Ragni N. Myasthenia gravis: management issues during pregnancy. European Journal of Obstetrics, Gynecology, and Reproductive Biology 2005; 121: 129-138.
64. Batocchi AP, Majolini L, Evoli A, Lino MM, Minisci C, Tonali P. Course and treatment of myasthenia gravis during pregnancy. Neurology 1999; 52: 447-452.
65. Motomura M, Johnston I, Lang B, Vincent A, Newsom-Davis J. An improved diagnostic assay for Lambert-Eaton myasthenic syndrome. Journal of Neurology, Neurosurgery and Psychiatry 1995; 58: 85-87.
66. Wirtz PW, Sotodeh M, Nijnuis M, et al. Difference in distribution of muscle weakness between myasthenia gravis and the Lambert-Eaton myasthenic syndrome. Journal of Neurology, Neurosurgery and Psychiatry 2002; 73: 766-768.
67. Wirtz PW, Willcox N, van der Slik AR, et al. HLA and smoking in prediction and prognosis of small cell lung cancer in autoimmune Lambert-Eaton myasthenic syndrome. Journal of Neuroimmunology 2005; 159: 230-237.
68. Maddison P, Newsom-Davis J. Treatment for Lambert-Eaton myasthenic syndrome. Cochrane Database of Systematic Reviews 2003; 2: CD003279.
69. McEvoy KM, Windebank AJ, Daube JR, Low PA. 3,4-Diaminopyridine in the treatment of Lambert-Eaton myasthenic syndrome. New England Journal of Medicine 1989; 321: 1567-1571.
70. Maddison P, Newsom-Davis J, Mills KR, Souhami RL. Favourable prognosis in Lambert-Eaton myasthenic syndrome and small-cell lung carcinoma. Lancet 1999; 353: 117-118.
71. Hart IK, Maddison P, Newsom-Davis J, Vincent A, Mills KR. Phenotypic variants of autoimmune peripheral nerve hyperexcitability. Brain 2002; 125(Pt 8): 1887-1895.
72. Hart IK, Waters C, Vincent A, et al. Autoantibodies detected to expressed K+ channels are implicated in neuromyotonia. Annals of Neurology 1997; 41: 238-246.
73. Newsom-Davis J, Mills KR. Immunological associations of acquired neuromyotonia (Isaacs' syndrome). Report of five cases and literature review. Brain 1993; 116(Pt 2):453-469.
74. Liguori R, Vincent A, Clover L, et al. Morvan's syndrome: peripheral and central nervous system and cardiac involvement with antibodies to voltage-gated potassium channels. Brain 2001; 124(Pt 12):2417-2426.
75. Hayat GR, Kulkantrakorn K, Campbell WW, Giuliani MJ. Neuromyotonia: autoimmune pathogenesis and response to immune modulating therapy. Journal of the Neurological Sciences 2000; 181: 38-43.
76. Shillito P, Molenaar PC, Vincent A, Leys K, Zheng W, van den Berg RJ, et al. Acquired neuromyotonia: evidence for autoantibodies directed against K+ channels of peripheral nerves. Annals of Neurology 1995; 38: 714-722.
77. Alessi G, De Reuck J, De Bleecker J, Vancayzeele S. Successful immunoglobulin treatment in a patient with neuromyotonia. Clinical Neurology and Neurosurgery 2000; 102: 173-175.
78. Nakatsuji Y, Kaido M, Sugai F, et al. Isaacs' syndrome successfully treated by immunoadsorption plasmapheresis. Acta Neurologica Scandinavica 2000; 102: 271-273.